We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CytoGenix Gene Silencing ssDNA Technology Patent Allowed in Europe and India

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CytoGenix Gene Silencing ssDNA Technology Patent Allowed in Europe and India"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

CytoGenix, Inc. has received notices of allowances for grant of patent applications covering the technology for expressing ssDNA In Vivo, from the Indian and European Community Patent Offices.

These notices follow the previous notice of allowance for these applications from the Peoples Republic of China.

Filed in 1999 and 2000, these patents cover the company’s single-strand DNA expression system covered by a US patent and by several patent applications in major world markets.

Used in the company’s Simplivir™ anti-herpes and CY303 anti inflammation products, an ssDNA gene silencing compound is active in reducing tumors in a melanoma experimental animal model.

Dr. Yin Chen, CytoGenix, Inc. Vice President, Chief Scientific Officer and a co-inventor of the single-strand DNA expression technology, states, "This is another step in our intellectual property strategy for this technology."

"These countries offer significant market opportunities and we are seeking appropriate licensees and partners."